Schrodinger

Q2 FY2026 EarningsQ2 FY26 results delivered a top-line beat with revenue of $58.9M exceeding the $47.2M consensus, driven by a $10M collaboration milestone in Drug Discovery. Non-GAAP net income significantly outperformed expectations due to a $45.9M gain from equity investments (Ajax Therapeutics acquisition), leading to a GAAP EPS of $0.08 vs. an expected loss of $0.39. ACV grew 27% YoY to $29.6M, while Software revenue fell 10% YoY during the transition to a hosted licensing model. Management raised FY26 Drug Discovery revenue guidance to $65M-$75M.